





Innovative Medicines Initiative

# The eTOX project: Its genesis and current achievements

Ferran Sanz

Director, Research Programme on Biomedical Informatics  
IMIM, Universitat Pompeu Fabra, Barcelona (Spain)

- **Project vision:** to develop innovative strategies and novel software tools to better predict the potential side-effects of new drug candidates on the basis of integrative approaches.
- Total budget: **18.7 M€**
- EC funding: **6.9 M€**
- In kind contribution from EFPIA companies: **10.1 M€**
- Duration: **7 years** (*from 1/2010 until 12/2016*)
- **13 EFPIA companies:** Novartis, Bayer, AstraZeneca, Boehringer, Esteve, GSK, Janssen, Lundbeck, Pfizer, Roche, Sanofi-Aventis, Servier, UCB.
- **11 academic institutions:** FIMIM, EBI, Erasmus Medical Center, ISCIII, ITEM, Universities of Leicester, Liverpool and Vienna, Free University of Amsterdam, Danish Technical University, Polytechnic University of Valencia.
- **6 SMEs:** Chemotargets, Intel:ligand, Lhasa, LMD, MN, Synapse



Present computational sciences allows the development of reliable predictive systems on the basis of the consideration of a wide and relevant scope of previous experience




## Opportunity for better toxicity predictions


The wealth of high quality toxicology data in the archives of pharmaceutical companies is not yet leveraged.


High Quality Tox Data Repository




Buried in toxicology archives







## Chronological progress of the extraction process (legacy reports of 2-4 week toxicity studies)



- Planned**  
Sum of cleared reports and those currently waiting for clearance
- Cleared**  
Reports submitted to CROs or in-house facilities for data extraction
- Extracted**  
Reports with processing by CROs or in-house facilities completed
- Vitic**  
Reports after quality checks, available at the Vitic eTOX database

Planned

Cleared

Extracted

Vitic


5246

4735

2708

1740








JOURNAL OF  
**CHEMICAL INFORMATION  
AND MODELING**

February 2011  
Volume 51  
Number 2  
[pubs.acs.org/jcim](http://pubs.acs.org/jcim)

ARTICLE

[pubs.acs.org/jcim](http://pubs.acs.org/jcim)

JOURNAL OF  
**CHEMICAL INFORMATION  
AND MODELING**






## A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity

Cristian Obiol-Pardo,<sup>†</sup> Julio Gomis-Tena,<sup>‡</sup> Ferran Sanz,<sup>†</sup> Javier Saiz,<sup>‡</sup> and Manuel Pastor<sup>\*,†</sup>


*J. Chem. Inf. Model.* 2011, 51, 483–492

New approach for the **predictive simulation of the long-QT syndrome** integrating simulations at three levels:





The **input** is the 2D structure of a possible drug



The **output** is the possible ECG alteration

Visit the project webpage: [www.etoxproject.eu](http://www.etoxproject.eu)



The screenshot shows the eTOX website homepage. At the top left is the eTOX logo. To its right is a banner image with four panels: test tubes, a petri dish with green spots, a stethoscope, and a DNA double helix. Below the banner is a navigation menu with tabs: HOME (highlighted in orange), PROJECT, CONSORTIUM, CONTACT, EVENTS / LINKS, NEWS, and MEMBERS. Below the menu are utility links: Print page, Send page, and a font size icon. The main content area has a 'LAST NEWS' sidebar on the left and a main section titled 'Welcome to the eTOX Website'. The main section contains two sub-sections: 'Objectives' and 'Funding'. The 'Objectives' section states: 'The eTOX project aims to develop a drug safety database from the pharmaceutical industry legacy toxicology reports and public toxicology data; innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline.' The 'Funding' section states: 'eTOX, under Grant Agreement n°115002, is funded by the Innovative Medicines Initiative Joint Undertaking (IMI-JU), a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA)'. On the right side of the main content area, there are two small images: one showing a rack of test tubes and another showing a person's hands using a pipette.

and subscribe to  
**the Newsletter**



# Key elements for a competitive EoI



1. Excellent matching of the proposal with the description of the topic
2. Innovative and feasible scientific contributions to the topic
3. Partners recognized as international experts in the field
4. Optimal consortium design (total coverage of the required scope of expertise, avoiding unjustified duplication of partner profiles)
5. Involvement of relevant SMEs
6. Attractive presentation of the proposal (text and layout)

